Jeffrey Lipman, MD

Professor Jeffrey Lipman AM, received his medical degree (MBBCh) from the University of Witwatersrand, South Africa and has specialist qualifications in anaesthesia (DA, FFA) and intensive care (FFA Crit Care, FCICM). More recently he received the award of AM - Member of the Order of Australia, for his contribution to Intensive Care. He recently stepped down from his two positions he held for over 20 years – that of Director of the Intensive Care Services, Royal Brisbane and Womens’ Hospital, as well as Professor and Head of Academy of Critical Care, The University of Queensland. He is the Executive Director of the Burns, Trauma, Critical Care Research Centre at this University. He has Professorial attachments at QUT, University of New South Wales, Chinese University of Hong Kong and his Alma Mater, University of Witwatersrand. Professor Lipman is a career Intensivist, having worked full-time in Intensive Care Units since 1979. His research interests include all aspects of infection management in intensive care. He has a special interest in the pharmacokinetics of antibiotics, an area in which he completed his MD through the Chinese University of Hong Kong where he still holds an Adjunct Professorial position. More recently has also obtained the DMed(Res) from The University of Queensland on refining beta-lactam dosing in critically ill patients. He has published over 30 book chapters and over 650 peer-reviewed articles including in high impact journals like NEJM, JAMA and Lancet Infectious Diseases. Professor Lipman has been the recipient of a number of National and International awards for his service to Intensive Care Medicine and was awarded 2017 Researcher of the Year by Metro North HHS. In 2020 he received his AM. Also in 2020, he was conferred Honorary Membership of European Society of Intensive Care Medicine (only 2nd Australian). He recently (Aug 2025) received the Metro North HHS Chief Executive’s award for his extensive research commitment. He has set up numerous clinical trials and as Principal Investigator has just published of a randomised clinical trial of 7200 patients with sepsis run in over 100 ICUs in 7 different countries.

MAJOR PUBLICATIONS IN 2024/2025 (24 in total) Koulenti D, Roger C, Lipman J Antibiotic dosing optimization in critically ill patients. Intensive Care Med. 2025 Mar 10. doi: 10.1007/s00134-025-07822-3 Roberts JA, Sime FB, Lipman J et al. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study. Intensive Care Med. 2025;51:302-317. doi: 10.1007/s00134-025-07793-5 Kong D, Roberts JA, Lipman J, et al. PIP/TAZ Consortium. A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly.. Clin Pharmacokinet. 2025;64:107-126. doi: 10.1007/s40262-024-01460-6. Abdul-Aziz MH….. Lipman J et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA. 2024;332:638-648. doi: 10.1001/jama.2024.9803. Dulhunty JM…et al, Lipman J; BLING III Study Investigators. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024;332:629-637. doi: 10.1001/jama.2024.9779